Illumina Rings the Bell at Nasdaq

Rhea-AI Summary

Illumina celebrated its 25th anniversary by ringing the closing bell at Nasdaq on March 30, 2023. Key executives, including Chief Commercial Officer Susan Tousi, highlighted the company's significant achievements in genomics over the past quarter-century. They pointed to advancements such as the capability to sequence 20,000 human genomes in a single year and rapid diagnosis of rare diseases. The company serves over 9,500 researchers and clinicians, transforming human health with genomic technology. Tousi emphasized the importance of collaboration with employees, customers, and partners to unlock the potential of the genome for improved health outcomes, marking this as the

Positive

• Notable milestone of 25 years in business.
• Ability to sequence 20,000 human genomes in a year.
• Significant advancements in diagnosing diseases quickly.

Negative

• None.

NORTHAMPTON, MA / ACCESSWIRE / April 6, 2023 / Illumina

Originally published on Illumina News Center

The Nasdaq closing bell in New York City signifies the end of a full day of trading on the stock market, a day of transactions made to benefit shareholders and companies, and propel business forward. Fittingly, Illumina representatives rang the closing bell on March 30, the day before the company completed its first 25 years in business.

In attendance were Illumina Chief Commercial Officer Susan Tousi, Chief Marketing Officer Kathryne Reeves, Chief People Officer Aimee Hoyt, and Head of Region for the Americas Nicki Berry. Joining these executives at the Nasdaq MarketSite in Times Square were Illumina employees-including some who have 25 years of service-and select customers.

Tousi rang the bell and spoke about the many genomic milestones and scientific achievements Illumina has made in the last quarter century, such as its ability to sequence 20,000 human genomes with one instrument in a single year.

"The more than 9,500 researchers and clinicians we serve are using these incredible advances in science to transform human health in ways that were unimaginable 25 years ago," she said. "Like diagnosing rare disease in a matter of days. Or catching the deadliest cancers at Stage 1 or Stage 0… or using genetics to fight climate change."

She concluded: "This is the Genome Era. And our employees, our customers, and our partners are leading it. Together, we're going to unlock the potential and the power of the genome to improve human health. And that is reason to celebrate!"

To read about the 25 greatest impacts in Illumina's 25 years of innovation, click here.

View additional multimedia and more ESG storytelling from Illumina on 3blmedia.com.

Contact Info:
Spokesperson: Illumina
Website: https://www.3blmedia.com/profiles/illumina
Email: info@3blmedia.com

SOURCE: Illumina

View source version on accesswire.com:
https://www.accesswire.com/747942/Illumina-Rings-the-Bell-at-Nasdaq

FAQ

What significant milestone did Illumina achieve in 2023?

Illumina marked its 25th anniversary by ringing the closing bell at Nasdaq on March 30, 2023.

Who represented Illumina during the Nasdaq closing bell ceremony?

Key executives included Chief Commercial Officer Susan Tousi and Chief Marketing Officer Kathryne Reeves.

What is the impact of Illumina's technology on human health?

Illumina's advancements enable rapid diagnosis of rare diseases and significant genomic research, improving health outcomes.

How many human genomes can Illumina sequence in a year?

Illumina can sequence 20,000 human genomes with one instrument in a single year.